CN109790583B - 对肺腺癌亚型分型的方法 - Google Patents

对肺腺癌亚型分型的方法 Download PDF

Info

Publication number
CN109790583B
CN109790583B CN201780044229.7A CN201780044229A CN109790583B CN 109790583 B CN109790583 B CN 109790583B CN 201780044229 A CN201780044229 A CN 201780044229A CN 109790583 B CN109790583 B CN 109790583B
Authority
CN
China
Prior art keywords
classifier
subtype
sample
hla
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044229.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109790583A (zh
Inventor
H·法鲁基
M·莱-高德曼
G·梅休
J·赛罗德
C·佩鲁
D·N·海耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Genecentric Diagnostics Inc
Original Assignee
University of North Carolina at Chapel Hill
Genecentric Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Genecentric Diagnostics Inc filed Critical University of North Carolina at Chapel Hill
Priority to CN202310993898.6A priority Critical patent/CN116987790A/zh
Publication of CN109790583A publication Critical patent/CN109790583A/zh
Application granted granted Critical
Publication of CN109790583B publication Critical patent/CN109790583B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780044229.7A 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法 Active CN109790583B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310993898.6A CN116987790A (zh) 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662337645P 2016-05-17 2016-05-17
US201662337591P 2016-05-17 2016-05-17
US62/337,591 2016-05-17
US62/337,645 2016-05-17
US201662396587P 2016-09-19 2016-09-19
US62/396,587 2016-09-19
US201662420836P 2016-11-11 2016-11-11
US62/420,836 2016-11-11
US201662425717P 2016-11-23 2016-11-23
US62/425,717 2016-11-23
PCT/US2017/033110 WO2017201165A1 (en) 2016-05-17 2017-05-17 Methods for subtyping of lung adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310993898.6A Division CN116987790A (zh) 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法

Publications (2)

Publication Number Publication Date
CN109790583A CN109790583A (zh) 2019-05-21
CN109790583B true CN109790583B (zh) 2023-08-25

Family

ID=60326094

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780044229.7A Active CN109790583B (zh) 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法
CN202310993898.6A Pending CN116987790A (zh) 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310993898.6A Pending CN116987790A (zh) 2016-05-17 2017-05-17 对肺腺癌亚型分型的方法

Country Status (6)

Country Link
US (2) US10934595B2 (enExample)
EP (1) EP3458612B1 (enExample)
JP (1) JP7241353B2 (enExample)
CN (2) CN109790583B (enExample)
CA (1) CA3024747A1 (enExample)
WO (1) WO2017201165A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950623A1 (en) 2014-05-30 2015-12-03 Myla LAI-GOLDMAN Methods for typing of lung cancer
WO2017201165A1 (en) 2016-05-17 2017-11-23 Genecentric Diagnostics, Inc. Methods for subtyping of lung adenocarcinoma
US11041214B2 (en) 2016-05-17 2021-06-22 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
EP3568145B1 (en) * 2017-01-13 2025-06-11 Mayo Foundation for Medical Education and Research Materials and methods for treating cancer
US12266426B2 (en) 2017-12-01 2025-04-01 Illumina, Inc. Method for administering a cancer treatment
KR102802863B1 (ko) * 2017-12-01 2025-04-30 일루미나, 인코포레이티드 약물 효능을 평가하기 위한 시스템 및 방법
WO2019160914A1 (en) 2018-02-13 2019-08-22 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
WO2020033866A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
EP3864165A4 (en) 2018-10-09 2022-08-03 Genecentric Therapeutics, Inc. DETECTION OF ORIGIN CANCER CELLS
WO2020081463A1 (en) * 2018-10-18 2020-04-23 Verily Life Sciences Llc Systems and methods for using image processing to generate inferences of biomarker for immunotherapy
CN112442535A (zh) * 2019-08-27 2021-03-05 上海善准生物科技有限公司 原发性肺腺癌分子分型及生存风险基因群及诊断产品和应用
AU2020364234A1 (en) * 2019-10-11 2022-04-07 Bioventures, Llc Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
CN112530595A (zh) * 2020-12-21 2021-03-19 无锡市第二人民医院 一种基于多分支链式神经网络的心血管疾病分类方法和装置
US20240182984A1 (en) * 2021-03-30 2024-06-06 Genecentric Therapeutics, Inc. Methods for assessing proliferation and anti-folate therapeutic response
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
WO2023010327A1 (zh) * 2021-08-04 2023-02-09 杭州浙大迪迅生物基因工程有限公司 一种人白三烯受体CysLTR2 mRNA RT-PCR检测用引物探针组和试剂盒
CN113903400B (zh) * 2021-10-29 2024-10-01 复旦大学附属华山医院 免疫相关疾病分子分型和亚型分类器的分类方法、系统
CN113981093B (zh) * 2021-11-26 2023-06-16 大连医科大学附属第一医院 Inpp4b基因表达量的检测剂在制备用于预测肺腺癌放疗敏感性的试剂盒的应用
CN114480644A (zh) * 2022-01-07 2022-05-13 深圳市龙华区人民医院 肺腺癌基于代谢基因的分子分型
CN114574589B (zh) * 2022-04-28 2022-08-16 深圳市第二人民医院(深圳市转化医学研究院) 标志物znf207在制备肺腺癌诊断试剂中的应用及诊断试剂盒
US20250327132A1 (en) * 2022-06-13 2025-10-23 The Government of the United States, as represented by the Director of the Defense Health Agency Lung Cancer-Related Biomarkers and Methods of Using the Same
CN115896282A (zh) * 2022-08-02 2023-04-04 上海市同仁医院 一种对甲状腺微小乳头状癌进行分子分型的方法以及分子标志物应用
CN115747332B (zh) * 2022-10-13 2026-06-16 复旦大学附属中山医院 一种检测肺腺癌smad4突变的试剂盒
CN115862876B (zh) * 2023-03-02 2023-05-26 北京师范大学 基于免疫微环境基因群预测肺腺癌患者预后的装置
CN116403648B (zh) * 2023-06-06 2023-08-01 中国医学科学院肿瘤医院 一种基于多维分析建立的小细胞肺癌免疫新分型方法
CN117491636B (zh) * 2023-11-21 2026-02-06 郑州大学 一种用于肺癌诊断的生物标志物及其应用
CN117635612A (zh) * 2024-01-25 2024-03-01 天津博思特医疗科技有限责任公司 一种肺部ct图像的识别方法
CN118460691B (zh) * 2024-07-11 2024-10-15 浙江省血液中心 用于hla基因多重扩增的引物组合物、应用和基因分型方法
CN119876392B (zh) * 2025-01-06 2025-08-12 上海市第六人民医院 一种用于辅助诊断肺腺癌骨转移的生物标志物
CN120445960B (zh) * 2025-05-07 2026-01-27 广州医科大学附属第一医院（广州呼吸中心） 一种外泌体表面标志物鉴别乳腺癌亚型的方法
CN121687186B (zh) * 2026-02-12 2026-05-26 山东大学齐鲁医院 H2ac19在肺腺癌检测以及治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007006792A (ja) * 2005-06-30 2007-01-18 Hitachi Software Eng Co Ltd 肺腺癌の胸膜浸潤を判別するための遺伝子セット
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1337667A2 (en) 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2008151110A2 (en) 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CN101509035A (zh) 2008-09-05 2009-08-19 中国人民解放军总医院 肺癌分型的基因序列及其应用
WO2013172926A1 (en) 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
US20150293098A1 (en) 2012-06-18 2015-10-15 The University Of North Carolina At Chapel Hill Methods for head and neck cancer prognosis
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
EP3037547A1 (en) * 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
US9885721B2 (en) * 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
CA2950623A1 (en) 2014-05-30 2015-12-03 Myla LAI-GOLDMAN Methods for typing of lung cancer
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3283654A4 (en) 2015-04-14 2018-12-12 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
WO2017201165A1 (en) 2016-05-17 2017-11-23 Genecentric Diagnostics, Inc. Methods for subtyping of lung adenocarcinoma
US11041214B2 (en) 2016-05-17 2021-06-22 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
US11739386B2 (en) * 2017-07-21 2023-08-29 Genecentric Therapeutics, Inc. Methods for determining response to PARP inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007006792A (ja) * 2005-06-30 2007-01-18 Hitachi Software Eng Co Ltd 肺腺癌の胸膜浸潤を判別するための遺伝子セット
WO2009146545A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation;Matthew D. Wilkerson等;《PloS ONE》;20120530;第7卷(第5期);摘要、图1B，第4页右侧Results、 *

Also Published As

Publication number Publication date
US20210222254A1 (en) 2021-07-22
EP3458612A4 (en) 2020-02-26
EP3458612A1 (en) 2019-03-27
US12139763B2 (en) 2024-11-12
JP7241353B2 (ja) 2023-03-17
JP2019516407A (ja) 2019-06-20
WO2017201165A1 (en) 2017-11-23
US20190338365A1 (en) 2019-11-07
EP3458612B1 (en) 2023-11-15
US10934595B2 (en) 2021-03-02
CA3024747A1 (en) 2017-11-23
CN116987790A (zh) 2023-11-03
CN109790583A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
CN109863251B (zh) 对肺鳞状细胞癌亚型分型的方法
CN109790583A (zh) 对肺腺癌亚型分型的方法
AU2019201577B2 (en) Cancer diagnostics using biomarkers
AU2018210695B2 (en) Molecular subtyping, prognosis, and treatment of bladder cancer
RU2721916C2 (ru) Способы прогнозирования рака предстательной железы
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
DK2644712T3 (en) A method for diagnosing neoplasms
CN110382521B (zh) 从氧化应激区分肿瘤抑制性foxo活性的方法
AU2013277971B2 (en) Molecular malignancy in melanocytic lesions
KR20140044341A (ko) 암에 대한 분자적 진단 검사
KR20150090246A (ko) 암을 위한 분자 진단 테스트
US20250283871A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
KR20140006898A (ko) 결장암 유전자 발현 시그니처 및 이용 방법
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
KR20160052729A (ko) 폐암에 대한 분자적 진단 검사
CN107077536A (zh) 使用靶基因表达的数学建模评价TGF‑β细胞信号传导途径的活性
AU2014373927B2 (en) Prostate cancer gene profiles and methods of using the same
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
EP4103752A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
WO2018132369A1 (en) Biomarkers predictive of anti-immune checkpoint response
CN101258249A (zh) 检测黑素瘤的方法和试剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20370825